Naltrexone: A Cornerstone of Medication-Assisted Treatment
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $7.15 | $214.49 (0%) | 🛒 Add to cart |
| 60 | $6.77 | $428.98 $405.93 (5%) | 🛒 Add to cart |
| 90 | $6.63
Best per pill | $643.47 $596.36 (7%) | 🛒 Add to cart |
Synonyms | |||
Naltrexone is a potent opioid antagonist medication that represents a significant advancement in the management of alcohol and opioid use disorders. As a non-addictive, long-acting agent, it functions by blocking the euphoric and sedative effects of opioids and reducing the craving for alcohol. Its efficacy is well-established in clinical settings, making it a foundational component of comprehensive treatment plans aimed at sustaining recovery and preventing relapse. This expert guide provides a detailed overview of its pharmacological profile, clinical applications, and essential safety information for healthcare professionals and informed patients.
Features
- Pharmacological Class: Pure opioid antagonist.
- Available Formulations: Oral tablets (50 mg standard) and extended-release intramuscular injectable suspension (Vivitrol® 380 mg/vial).
- Mechanism of Action: Competitively binds to mu-opioid receptors, displacing agonist drugs and preventing their effects.
- Bioavailability: Oral formulation has 5–40% bioavailability due to significant first-pass metabolism; injectable formulation provides continuous release over approximately four weeks.
- Half-Life: Oral: approximately 4–13 hours; active metabolite 6-beta-naltrexol: 13 hours. Injectable: release kinetics provide effective receptor blockade for one month.
- Metabolism: Primarily hepatic, via dihydrodiol dehydrogenase.
- Excretion: Primarily renal.
Benefits
- Sustains Recovery: Significantly reduces the rate of relapse in both alcohol and opioid dependence by mitigating cravings.
- Non-Addictive Profile: Lacks the abuse potential, euphoric effects, or physiological dependence associated with agonist therapies, simplifying treatment.
- Supports Psychosocial Therapy: By blocking the rewarding effects of substances, it allows patients to fully engage in and benefit from counseling and behavioral therapies.
- Flexible Dosing Options: The availability of both daily oral and monthly injectable formulations allows for personalized treatment plans that enhance adherence.
- Improves Long-Term Outcomes: Demonstrated efficacy in helping patients maintain abstinence, thereby improving overall quality of life and reducing health complications associated with substance use.
Common use
Naltrexone is FDA-approved for two primary indications. First, for the treatment of alcohol use disorder (AUD), where it is used to help maintain abstinence by reducing the craving for alcohol and diminishing its pleasurable effects. Second, for the prevention of relapse to opioid dependence following opioid detoxification. It is critical that patients are fully opioid-free before initiation to avoid precipitating acute withdrawal. Off-label, it is sometimes investigated for other compulsive behaviors, though robust evidence for these uses is still developing.
Dosage and direction
For Alcohol Dependence:
- Oral: Initiation typically begins after a minimum of 7-10 days of confirmed alcohol abstinence. The recommended dose is 50 mg once daily. Some protocols may utilize a reduced schedule (e.g., 100 mg every other day or 150 mg every third day) to improve adherence, though daily dosing is standard.
- Injectable (Vivitrol®): 380 mg delivered via intramuscular gluteal injection every 4 weeks or once monthly. A patient must be opioid-free for a minimum of 7–10 days prior to the first injection.
For Opioid Dependence:
- Oral: Initiation must only occur after a patient is completely opioid-free. A challenge test with a naloxone injection is often recommended to confirm the absence of physical dependence. The standard maintenance dose is 50 mg once daily.
- Injectable (Vivitrol®): 380 mg IM every 4 weeks. The opioid-free period must be strictly adhered to (minimum 7–10 days for short-acting opioids; longer for methadone or buprenorphine).
General Direction: Oral tablets can be taken with or without food. The injectable formulation must be administered by a healthcare professional.
Precautions
- Hepatotoxicity: Naltrexone has been associated with dose-related hepatocellular injury. Although uncommon at recommended doses, hepatic transaminases should be monitored before and during therapy, especially in patients with pre-existing liver disease.
- Depression and Suicidality: As with many treatments for substance use disorders, emergence of depressive symptoms and suicidal ideation has been observed. Patients should be monitored for the development of these symptoms.
- Opioid Tolerance Loss: Patients will have a reduced tolerance to opioids. If they resume opioid use after a period of abstinence while on naltrexone, attempting to overcome the blockade by taking large doses of opioids can lead to fatal respiratory depression or overdose.
- Injection Site Reactions: The intramuscular injection can cause pain, tenderness, induration, swelling, erythema, bruising, or pruritus. Rarely, more serious reactions like necrosis or sterile abscess can occur.
- Eosinophilic Pneumonia: There have been postmarketing reports of eosinophilic pneumonia associated with the injectable formulation.
Contraindications
- Current physical dependence on opioids or acute opioid withdrawal.
- Failure to pass a naloxone challenge test or having a positive urine screen for opioids.
- Acute hepatitis or liver failure.
- Known hypersensitivity to naltrexone or any component of the formulation (e.g., polylactide-co-glycolide (PLG) in the injectable suspension).
- The injectable form is contraindicated in patients with thrombocytopenia or any coagulation disorder.
Possible side effect
Common side effects are often transient and may include:
- Nausea (~10%)
- Headache (~7%)
- Dizziness (~4%)
- Nervousness, fatigue, insomnia
- Abdominal pain/cramps, vomiting
- Anxiety, low energy
- Joint and muscle pain
- Injection site reactions (for Vivitrol®: very common, including pain, tenderness, induration)
Less common but more serious side effects require medical attention:
- Signs of hepatitis (e.g., dark urine, jaundice, right upper quadrant pain)
- Severe depression or suicidal thoughts
- Signs of an allergic reaction (e.g., difficulty breathing, hives, swelling of the face or throat)
- Pneumonia symptoms (e.g., shortness of breath, wheezing, cough)
Drug interaction
- Opioid Analgesics: Naltrexone will block the therapeutic effects of opioid pain medications, including those used for surgical analgesia, and may precipitate withdrawal in dependent individuals. Opioid analgesia will be ineffective; non-opioid analgesics must be used.
- Opioid-Containing Medications: Will block the effects of cough suppressants (e.g., codeine, hydrocodone) and antidiarrheal drugs (e.g., diphenoxylate/atropine).
- Thioridazine: Naltrexone may increase the somnolence induced by thioridazine.
- CYP450 Enzymes: Naltrexone is a minor substrate of CYP450 enzymes; interactions with inducers or inhibitors of these enzymes are not expected to be clinically significant.
Missed dose
- Oral Formulation: If a daily dose is missed, it should be taken as soon as possible. However, if it is almost time for the next dose, the missed dose should be skipped and the regular dosing schedule resumed. Do not double the dose.
- Injectable Formulation: The next injection should be scheduled as soon as possible. A healthcare provider will determine the appropriate schedule to re-establish monthly dosing.
Overdose
There is no clinical experience with naltrexone overdose in humans. High doses (300 mg/day) have been administered and produced nausea and abdominal pain. As naltrexone is a pure antagonist, it does not cause respiratory depression. In cases of suspected overdose, supportive and symptomatic treatment is indicated. The patient should be monitored closely.
Storage
- Oral Tablets: Store at room temperature (20°–25°C or 68°–77°F) in a tight, light-resistant container. Keep out of reach of children.
- Injectable Suspension (Vivitrol®): Refrigerate at 2°–8°C (36°–46°F) in the original carton to protect from light. It can be left at room temperature for no more than 7 days prior to administration. Do not freeze. The product must be administered promptly after mixing.
Disclaimer
This information is intended for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here.
Reviews
“Naltrexone, particularly in its injectable form, has been a game-changer in my practice. It removes the daily burden of pill-taking for patients, which dramatically improves adherence. The key to success is proper patient selection and ensuring complete detoxification beforehand. The reduction in craving reports from my patients with alcohol use disorder is consistently significant.” – Addiction Psychiatrist, 15 years of experience.
“The pharmacological blockade provided by naltrexone offers a unique ‘safety net’ for patients in early recovery. It provides a crucial period where impulsive use does not result in reward, allowing cognitive behavioral strategies to take root. Monitoring liver function is a standard part of our protocol, and we have encountered very few issues at therapeutic doses.” – Clinical Pharmacist specializing in Substance Use Disorders.